Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.54
- Piotroski Score 2.00
- Grade Buy
- Symbol (ARCT)
- Company Arcturus Therapeutics Holdings Inc.
- Price $16.27
- Changes Percentage (1.56%)
- Change $0.25
- Day Low $15.71
- Day High $17.37
- Year High $45.00
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
- Last Earnings 12/27/2012
- Ex-Dividend for 5/16 Dividend 01/08/2013
- Dividend Payable 01/15/2013
- Today N/A
- Next Earnings (Estimated) 03/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $67.00
- High Stock Price Target $140.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.03
- Trailing P/E Ratio -7.9
- Forward P/E Ratio -7.9
- P/E Growth -7.9
- Net Income $-29,725,000
Income Statement
Quarterly
Annual
Latest News of ARCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UK weather: Met Office issues woolly jumpers alert as Arctic blast arrives
Northern England and Scotland will experience subzero temperatures after an unusually mild spell, as the UK Met Office warns of an Arctic blast bringing sleet, snow, and ice. Wintry weather warnings h...
By The Guardian | 1 day ago -
How An Arctic Town With More Polar Bears Than People Became A Culinary Destination
In Churchill, Manitoba, known for polar bears and Northern Lights, culinary delights await with local ingredients like elk and cloudberries. From dining in a Tundra Buggy to experiencing the Aurora Ov...
By Forbes | 5 days ago -
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...
Meiji plans to sell 4.5 million flu vaccines in Japan, with the full launch expected by December. The Phase 2 cystic fibrosis study will evaluate multiple doses and recruit non-responders to CFTR modu...
By Yahoo! Finance | 1 week ago
